Autifony Therapeutics Limited logo

Autifony Therapeutics Limited

Autifony Therapeutics develops novel pharmaceutical treatments for hearing disorders. Autifony Therapeutics is a biotech company that focus on modulation of Kv3 channels for the development of high value, novel medicines to treat hearing disorders and serious disorders of the central nervous system, such as schizophrenia.

Autifony Therapeutics was formed as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSKs Neuroscience Centre of Excellence for Drug Discovery. Autifonys head office is at the Imperial College Incubator in London, and it has a subsidiary with medicinal chemistry and biology labs based in Verona, Italy.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://autifony.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, SG1 2FX
Hertfordshire
United Kingdom
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/autifony-therapeutics
” connections=”true” suffix=””]

Dec 2017, Autifony and Boehringer Ingelheim signed an agreement about certain aspects of Autifonys voltage gated potassium channel modulator platform. Boehringer Ingelheim now has an exclusive option to purchase Autifonys Kv3.1/3.2 positive modulator platform, AUT00206 Included in the agreement. The total potential transaction may sum up to ‹627.5 million.

March 2017, Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund for initiation of a research programme with a novel approach to the treatment of dementia.

In July 2015, Autifony raised £8 Mn extension to its Series A funding round. Autifony previously raised over £15 Mn in a Series A round from SV Life Sciences, Imperial Innovations, Pfizer Venture Investments, the International Biotechnology Trust PLC (IBT), and UCL Business.

In April 2015, Autifony received £3.3 Mn funding, mainly from the Biomedical Catalyst, jointly funded by Innovate UK and the Medical Research Council, to progress AUT00206 into clinical trials for the treatment of schizophrenia.